Malignant Digestive System Neoplasm

In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC)

PMID 18316791 · Amado et al., 2008 · Open in CIViC

KRAS mutations have been reported in 30-50% of colorectal carcinomas.

PMID 16953233 · Oliveira et al., 2007 · Open in CIViC

KRAS mutations have been reported in 30-50% of colorectal carcinomas.

PMID 2547513 · Bos, 1989 · Open in CIViC

KRAS mutations have been reported in 30-50% of colorectal carcinomas.

PMID 8462792 · Benhattar et al., 1993 · Open in CIViC

In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

In vivo genetic evidence for context-specific effector pathways of oncogenic Kras in PDAC and define cell autonomous Kras → PI3K → PDK1 signaling as a therapeutic target in pancreatic cancer. Targeti… (full text at CIViC)

PMID 23453624 · Eser et al., 2013 · Open in CIViC

In a stage IIA (T3N0M0) sigmoid colorectal cancer patient with multiple lung metastases harboring KRAS G12D mutation, a partial response to regorafenib monotherapy was reported. The patient was treate… (full text at CIViC)

PMID 26870193 · Kawasaki et al., 2016 · Open in CIViC

In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 … (full text at CIViC)

PMID 26161928 · Camaj et al., 2015 · Open in CIViC

A phase 1 dose‑escalation and dose‑expansion study in patients with previously treated advanced KRAS p.G12D mutant pancreatic ductal adenocarcinoma (NCT05382559; n = 203 overall; n = 21 PDAC treated a… (full text at CIViC)

PMID 41879829 · Park et al., 2026 · Open in CIViC

In an in vitro study, colorectal cancer SW48 cell line expressing KRAS G12D mutation demonstrated reduced sensitivity to sunitinib treatment (IC50: 4.9uM vs. 2.6uM, P<0.05) compared to SW48 cells expr… (full text at CIViC)

PMID 23455880 · Modest et al., 2013 · Open in CIViC

A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After… (full text at CIViC)

PMID 27959684 · Tran et al., 2016 · Open in CIViC

In an in vitro study, PLX-4032 cell lines expressing KRAS G12D mutation demonstrated resistance to vemurafenib treatment, compared to PDA_014 cell expressing BRAF V600E mutation (a known sensitizing m… (full text at CIViC)

PMID 25855536 · Witkiewicz et al., 2015 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring CDKN2A_p16 R80* and KRAS G12D, was treated with Palbocicl… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (82 y/F) with pancreatic cancer harboring GNAS R201C, KRAS G12D and, NF1 D1976fs, was treated with … (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (69 y/M) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were obs… (full text at CIViC)

PMID 18316791 · Amado et al., 2008 · Open in CIViC

KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.

PMID 18202412 · Lièvre et al., 2008 · Open in CIViC

This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28).

PMID 22983505 · Ogura et al., 2013 · Open in CIViC

In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (as well as G12D) was associated with poorer prognosis (95% confidence interval of HR between 1.11 and 2.28).

PMID 22983505 · Ogura et al., 2013 · Open in CIViC